Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Ascendis pharma a::S save search
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism
Published: 2023-05-01 (Crawled : 12:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 8.93%
H: 14.16%
C: 13.82%
drug food response
Ascendis Pharma Reports First Quarter 2023 Financial Results
Published: 2023-04-27 (Crawled : 00:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.0%
H: 1.46%
C: 0.71%
pharma financial results
Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27
Published: 2023-04-13 (Crawled : 14:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.1%
H: 1.32%
C: 0.63%
pharma conference business update financial results
Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism
Published: 2023-01-04 (Crawled : 15:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 1.46%
H: 0.58%
C: -0.33%
Ascendis Pharma Reports Third Quarter 2022 Financial Results
Published: 2022-11-02 (Crawled : 23:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: -1.41%
H: 2.31%
C: -0.97%
pharma financial results
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
Published: 2022-10-31 (Crawled : 17:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 2.08%
H: 4.19%
C: 2.41%
fda review
New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022
Published: 2022-09-12 (Crawled : 18:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.77%
H: 3.05%
C: 1.42%
week trial
Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism
Published: 2022-08-31 (Crawled : 13:20) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.17%
H: 4.92%
C: 3.85%
fda pharma drug application
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
Published: 2022-08-10 (Crawled : 22:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 1.18%
H: 1.14%
C: 0.94%
pharma results
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.58%
H: 3.67%
C: 2.3%
pharma conference update results
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
Published: 2022-05-23 (Crawled : 17:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
pharma commercial
Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2
Published: 2022-02-25 (Crawled : 19:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
financial results conference results
Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Published: 2022-02-10 (Crawled : 00:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: -2.38%
H: 0.0%
C: 0.0%
health thc conference svb leerink global pharma
Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone DeficiencyTransCon hGH
Published: 2022-01-13 (Crawled : 14:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 2.82%
H: 4.09%
C: -3.21%
europe approval growth hormone growth hormone pharma
Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: -0.56%
H: 2.19%
C: -1.93%
pharma
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH
Published: 2021-06-11 (Crawled : 00:20) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: -0.67%
H: 2.33%
C: 2.27%
food drug pharma
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
Published: 2021-03-10 (Crawled : 12:41) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.35%
H: 0.47%
C: -1.09%
disease endocrine diseases endocrine rare
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.